ERAXIS is indicated for use in the treatment of the following fungal infections:
Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis)
(see CLINICAL STUDIES and MICROBIOLOGY).
ERAXIS has not been studied in endocarditis, osteomyelitis, and meningitis due to Candida,
and has not been studied in sufficient numbers of neutropenic patients to determine efficacy in
this group.
Esophageal candidiasis (see CLINICAL STUDIES, Table 7 for higher relapse rates off ERAXIS
therapy).
Specimens for fungal culture and other relevant laboratory studies (including histopathology)
should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may
be instituted before the results of the cultures and other laboratory studies are known. However,
once these results become available, antifungal therapy should be adjusted accordingly.
